GlassScriptPhysician profile
John S Kang
NPI 1427459734
$93,031.29
in general payments reported to CMS, 2019-2025
35 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $276 · 2021: $1,562 · 2022: $1,346 · 2023: $12K · 2024: $30K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Honoraria: $25K · Food and Beverage: $14K · Travel and Lodging: $6,283 · Consulting Fee: $6,246 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,800.00 |
| Honoraria | $25,337.50 |
| Food and Beverage | $14,021.81 |
| Travel and Lodging | $6,282.82 |
| Consulting Fee | $6,246.22 |
| Education | $159.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43,550.36 | 2020-2025 | Krystexxa, Repatha, Tavneos |
| Calliditas Therapeutics US INC. | $28,934.76 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $8,296.70 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $4,035.51 | 2020-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $1,085.14 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $806.64 | 2023-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $764.05 | 2023-2025 | Filspari |
| Novo Nordisk INC | $733.95 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.93 | 2023-2025 | Jardiance, Tradjenta |
| Vifor Pharma, INC. | $510.75 | 2022-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $400.50 | 2023-2025 | Velphoro, Velphoro |
| Mannkind Corporation | $364.99 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $361.05 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $339.16 | 2022-2025 | Jynarque, Voyxact |
| Intuity Medical INC | $294.64 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $201.66 | 2025 | Yorvipath |
| Lilly USA, LLC | $200.86 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $187.45 | 2024-2025 | |
| Exact Sciences Corporation | $186.79 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merz North America, INC. | $185.76 | 2021 | |
| Thd America, INC. | $153.86 | 2024 | |
| Ardelyx, INC. | $148.86 | 2025 | Xphozah 30 Mg |
| Medtronic, INC. | $136.65 | 2022-2024 | Minimed 780g, Intellis Adaptivestim |
| Aurinia Pharma U.S., INC. | $87.54 | 2024 | Lupkynis |
| Amarin Pharma, INC. | $58.81 | 2021 | |
| Abbott Laboratories | $56.05 | 2024 | Freestyle Libre |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $53.08 | 2025 | Voyxact |
| Xeris Pharmaceuticals, INC. | $42.40 | 2022-2023 | Recorlev |
| Alnylam Pharmaceuticals INC. | $30.45 | 2025 | Givlaari |
| Akebia Therapeutics INC | $23.08 | 2021 | |
| Glaxosmithkline, LLC. | $21.68 | 2023 | Benlysta |
| Kyowa Kirin, INC. | $15.00 | 2024 | Crysvita |
| Angiodynamics, INC. | $14.95 | 2022 | |
| Corcept Therapeutics | $14.67 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.